These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 26987746)

  • 1. Japanese regulation of biosimilar products: past experience and current challenges.
    Arato T
    Br J Clin Pharmacol; 2016 Jul; 82(1):30-40. PubMed ID: 26987746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Japanese Regulatory Systems for Generics and Biosimilars.
    Kuribayashi R; Sawanobori K
    J Pharm Sci; 2018 Mar; 107(3):785-787. PubMed ID: 29113922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar regulation in the EU.
    Kurki P; Ekman N
    Expert Rev Clin Pharmacol; 2015; 8(5):649-59. PubMed ID: 26294076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Historical Overview of Regulatory Approvals and PMDA Assessments for Biosimilar Products in Japan During 2009-2022.
    Kuribayashi R; Nakano A; Hariu A; Kishioka Y; Honda F
    BioDrugs; 2023 Jul; 37(4):443-451. PubMed ID: 37227657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are biosimilars and are they important?
    Drug Ther Bull; 2013 May; 51(5):57-60. PubMed ID: 23657197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of biosimilar medicines and current perspectives on interchangeability and policy.
    O'Callaghan J; Barry SP; Bermingham M; Morris JM; Griffin BT
    Eur J Clin Pharmacol; 2019 Jan; 75(1):1-11. PubMed ID: 30187103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilars: Implications for health-system pharmacists.
    Lucio SD; Stevenson JG; Hoffman JM
    Am J Health Syst Pharm; 2013 Nov; 70(22):2004-17. PubMed ID: 24173009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory watch: Innovation in biologic new molecular entities: 1986-2014.
    Miller KL; Lanthier M
    Nat Rev Drug Discov; 2015 Feb; 14(2):83. PubMed ID: 25633785
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulatory Perspective of International Agencies for Development of Biosimilar Products (Monoclonal Antibodies): An Overview.
    Sharma A; Khante S; Mahadik KR; Gaikwad VL
    Ther Innov Regul Sci; 2020 Sep; 54(5):965-977. PubMed ID: 31933180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global regulatory standards for the approval of biosimilars.
    Mounho B; Phillips A; Holcombe K; Grampp G; Lubiniecki T; Mollerup I; Jones C
    Food Drug Law J; 2010; 65(4):819-37, ii-iii. PubMed ID: 24479248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Biosimilars: regulatory status for approval].
    Herrero Ambrosio A
    Farm Hosp; 2010 Mar; 34 Suppl 1():16-8. PubMed ID: 20920853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Considerations related to comparative clinical studies for biosimilars.
    Rathore AS; Stevenson JG; Chhabra H
    Expert Opin Drug Saf; 2021 Mar; 20(3):265-274. PubMed ID: 33455482
    [No Abstract]   [Full Text] [Related]  

  • 16. [The story of biosimilars--chance or threat?].
    Woroń J; Kocić I
    Pol Merkur Lekarski; 2014 Nov; 37(221):311-5. PubMed ID: 25546996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Path Towards a Tailored Clinical Biosimilar Development.
    Schiestl M; Ranganna G; Watson K; Jung B; Roth K; Capsius B; Trieb M; Bias P; Maréchal-Jamil J
    BioDrugs; 2020 Jun; 34(3):297-306. PubMed ID: 32266678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: Key regulatory considerations and similarity assessment tools.
    Kirchhoff CF; Wang XM; Conlon HD; Anderson S; Ryan AM; Bose A
    Biotechnol Bioeng; 2017 Dec; 114(12):2696-2705. PubMed ID: 28842986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biosimilars: A consideration of the regulations in the United States and European union.
    Daller J
    Regul Toxicol Pharmacol; 2016 Apr; 76():199-208. PubMed ID: 26732800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.